New investigational drugs for the treatment of neuropathic pain

Bibliography

• Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain 2011;152:2204-5
   PubMed Web of Science ®Google Scholar
• Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14-27
   PubMed Web of Science ®Google Scholar
• Haanpää M. The assessment of neuropathic pain patients. Pain Manag 2013;3:59-65
   PubMedGoogle Scholar
• Backonja MM. Defining neuropathic pain. Anesth Analg 2003;97:785-90
   PubMed Web of Science ®Google Scholar
• Babos MB, Grady B, Wisnoff W, et al. Pathophysiology of pain. Dis Mon 2013;59:330-58
   PubMed Web of Science ®Google Scholar
• Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013;111:105-11
   PubMed Web of Science ®Google Scholar
• Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 2005;5:823-30
   PubMedGoogle Scholar
• Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther 2004;26:951-79
   PubMed Web of Science ®Google Scholar
• Backonja M, Woolf CJ. Future directions in neuropathic pain therapy: closing the translational loop. Oncologist 2010;15(Suppl 2):24-9
   PubMedGoogle Scholar
• Mick G, Baron R, Finnerup NB. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag 2012;2:71-7
   PubMedGoogle Scholar
• Hartrick CT. Noradrenergic reuptake inhibition in the treatment of pain. Expert Opin Investig Drugs 2012;21:1827-34
   PubMed Web of Science ®Google Scholar
• Richards N, McMahon SB. Targeting novel peripheral mediators for the treatment of chronic pain. Br J Anaesth 2013;111:46-51
   PubMed Web of Science ®Google Scholar
• Lötsch J, Doehring A, Mogil JS, et al. Functional genomics of pain in analgesic drug development and therapy. Pharmacol Ther 2013;139:60-70
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305
   PubMed Web of Science ®Google Scholar
• Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003;8:149-54
   PubMedGoogle Scholar
• Burgess G, Williams D. The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest 2010;120:3753-9
   PubMed Web of Science ®Google Scholar
• Sałat K, Moniczewski A, Librowski T. Transient receptor potential channels - emerging novel drug targets for the treatment of pain. Curr Med Chem 2013;20(11):1409-36
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Wickenden AD, Chaplan SR. Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics 2009;6:663-78
   PubMed Web of Science ®Google Scholar
• Colombo E, Francisconi S, Faravelli L, et al. Ion channel blockers for the treatment of neuropathic pain. Future Med Chem 2010;2:803-42
   PubMed Web of Science ®Google Scholar
• Clark AK, Old EA, Malcangio M. Neuropathic pain and cytokines: current perspectives. J Pain Res 2013;21:803-14
   Google Scholar
• Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a ’hot’ medicine is reignited. Expert Opin Pharmacother 2010;11:1359-71
   PubMed Web of Science ®Google Scholar
• Choi KH. The design and discovery of T-type calcium channel inhibitors for the treatment of central nervous system disorders. Expert Opin Drug Discov 2013;8:919-31
   PubMed Web of Science ®Google Scholar
• Szallasi A, Sheta M. Targeting TRPV1 for pain relief: limits, losers and laurels. Expert Opin Investig Drugs 2012;21:1351-69
   PubMed Web of Science ®Google Scholar
• Pexton T, Moeller-Bertram T, Schilling JM, et al. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert Opin Investig Drugs 2011;20:1277-84
   PubMed Web of Science ®Google Scholar
• Todorovic SM, Jevtovic-Todorovic V. T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br J Pharmacol 2011;163:484-95
   PubMed Web of Science ®Google Scholar
• Yang P, Wang L, Xie XQ. Latest advances in novel cannabinoid CB2 ligands for drug abuse and their therapeutic potential. Future Med Chem 2012;4:187-204
   PubMed Web of Science ®Google Scholar
• Gether U, Andersen PH, Larsson OM, et al. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 2006;27:375-83
   PubMed Web of Science ®Google Scholar
• Dib-Hajj SD, Binshtok AM, Cummins TR, et al. Voltage-gated sodium channels in pain states: Role pathophysiology and target for treatment. Brain Res Rev 2009;60:65-83
   PubMed Web of Science ®Google Scholar
• Theile JW, Cummins TR. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front Pharmacol 2011;2:1-54
   Google Scholar
• Zhang XF, Shieh CC, Chapman ML, et al. A-887826 is a structurally novel, potent and voltage-dependent Nav1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats. Neuropharmacology 2010;59:201-7
   PubMed Web of Science ®Google Scholar
• Nanayakkara B, Phillips D, Russell M. The molecular pathogenesis of primary erythromelalgia, a painful inherited syndrome – An update. MSJA 2012;4:33-8
   Google Scholar
• Mantegazza M, Curia G, Biagini G, et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010;9:413-24
   PubMed Web of Science ®Google Scholar
• Rahman W, Dickenson AH. Voltage gated sodium and calcium channel blockers for the treatment of chronic inflammatory pain. Neurosci Lett 2013;557:19-26
   PubMed Web of Science ®Google Scholar
• Eijkelkamp N, Linley JE, Baker MD, et al. Neurological perspectives on voltage-gated sodium channels. Brain 2012;35:2585-612
   Google Scholar
• Wickenden A. Ion channel drug discovery: challenges and future directions. Future Med Chem 2012;4:661-79
   PubMed Web of Science ®Google Scholar
• Ali Z, Palmer JE, Goli V. Anticonvulsant clinical. In: McMahon S, Koltzenburg M, Tracey I, Turk D, editors. Wall and Melzack’s texbook of pain. Elsevier; Barcelona: 2006
   Google Scholar
• Chapman ML, Printzenhoff D, Lin Z, et al. Characterization of a novel subtype-selective inhibitor of human Nav1.7 voltage-dependent sodium channels, 140.06/C25, 2012 Neuroscience Meeting Planner. Society for Neuroscience; New Orleans, LA: 2012. Online
   Google Scholar
• Evaluation of the efficacy and safety of single doses of PF-05089771 in patients with primary (inherited) erythromelalgia (IEM). Available from: http://clinicaltrials.gov/ct2/show/NCT01769274?term=PF-05089771&rank=7
   Google Scholar
• Lotsch J, Geisslinger G. Pharmacogenetics of new analgesics. Br J Pharmacol 2011;163:447-60
   PubMed Web of Science ®Google Scholar
• Zakrzewska JM, Palmer J, Ettlin DA, et al. Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia. Trials 2013;14:402
   PubMed Web of Science ®Google Scholar
• Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 2006;52(1):77-92
   PubMed Web of Science ®Google Scholar
• Goldberg YP, Price N, Namdari R, et al. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain 2012;153:80-5
   PubMed Web of Science ®Google Scholar
• Goldberg YP, Pimstone SN, Namdari R, et al. Human Mendelian pain disorders: a key to discovery and validation of novel analgesics. Clin Genet 2012;82:367-73
   PubMed Web of Science ®Google Scholar
• Crow M, Denk F, McMahon SB. Genes and epigenetic processes as prospective pain targets. Genome Med 2013;5:12
   PubMed Web of Science ®Google Scholar
• Perret D, Luo ZD. Targeting voltage-gated calcium channels for neuropathic pain management. Neurotherapeutics 2009;6:679-92
   PubMed Web of Science ®Google Scholar
• Vink S, Alewood PF. Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for trearment of neuropathic pain. Br J Pharmacol 2012;167:970-89
   PubMed Web of Science ®Google Scholar
• Corrigan MHN. Calcium channel treats chronic pain. Drug Discovery and Development. 2012. Available from: www.dddmag.com/articles/2012/05/calcium-channel-treats-chronic-pain
   Google Scholar
• Lee M, Snutch T. Z160: a potent and state-dependent, small molecule blocker of N-type calcium channels effective in nonclinical models of neuropathic pain. J Pain 2013;14:S71
   Web of Science ®Google Scholar
• Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy. Available from: http://clinicaltrials.gov/ct2/show/NCT01655849?term=Z160&rank=1
   Google Scholar
• Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia (PHN). Available from: http://clinicaltrials.gov/ct2/show/NCT01757873?term=Z160&rank=2
   Google Scholar
• Jacus MO, Uebele VN, Renger JJ, Todorovic SM. Presynaptic CaV channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J Neurosci 2012;32:9374-81
   PubMed Web of Science ®Google Scholar
• Tringham E, Powell KL, Cain SM, et al. T-type calcium channel blockers that attenuate thalamic buers firing and suppress absence seizures. Sci Transl Med 2012;4:1-13
   Google Scholar
• Short G, Lee M, Snutch T. Z944: a first in-class T-type calcium channel blocker effective in nonclinical models of acute and inflammatory pain J Pain. 2013;14:S71
   Google Scholar
• Hassan P, Ramesh K, Yanbing D, et al. N-piperidinyl acetamide derivatives as calcium channel blockers. US patent US8569344; 2013
   Google Scholar
• Nemoto W, Nakagawasai O, Yaoita F, et al. Angiotensin II produces nociceptive behavior through spinal AT1 receptor-mediated p38 mitogen-activated protein kinase activation in mice. Mol Pain 2013;9:38
   PubMed Web of Science ®Google Scholar
• Pavel J, Tang H, Brimijoin S, et al. Expression and transport of Angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat. Brain Res 2008;1246:111-22
   PubMed Web of Science ®Google Scholar
• Pavel J, Oroszova Z, Hricova L, et al. Effect of subpressor dose of angiotensin II on pain-related behavior in relation with neuronal injury and activation of satellite glial cells in the rat dorsal root ganglia. Cell Mol Neurobiol 2013;33:681-8
   PubMed Web of Science ®Google Scholar
• Saavedra JM, Ando H, Armando I, et al. Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept 2005;128:227-38
   PubMed Web of Science ®Google Scholar
• Anand U, Facer P, Yiangou Y, et al. Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 2013;17:1012-26
   PubMed Web of Science ®Google Scholar
• Gallinat S, Yu M, Dorst A, et al. Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res 1998;57:111-22
   PubMedGoogle Scholar
• Tan YH, Li K, Chen XY, et al. Activation of Src family kinases in spinal microglia contributes to formalin-induced persistent pain state through p38 pathway. J Pain 2012;13:1008-15
   PubMed Web of Science ®Google Scholar
• Smith MT, Woodruff TM, Wyse BD, et al. A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Med 2013;14:1557-68
   PubMed Web of Science ®Google Scholar
• Smith MT, Wyse BD, Edwards SR, et al. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med 2013;14:692-705
   PubMed Web of Science ®Google Scholar
• Smith MT, Wyse BD. Method of treatment or prophylaxis. US patent US7795275; 2010
   Google Scholar
• Smith MT. Method of treatment or prophylaxis inflammatory pain. Patent EP1996183; 2008
   Google Scholar
• Takai S, Song K, Tanaka T, et al. Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci 1996;59:PL331-6
   PubMed Web of Science ®Google Scholar
• Rice ASC, Dworkin RH, McCarthy TD, et al. EMA401, an orally administrated highly selective angiotensin II type 2 receptor antagonist, as novel treatment for postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Available from: www.anzctr.org
   Google Scholar
• Kumar V, Mahal BA. NGF - the TrkA to successful pain treatment. J Pain Res 2012;5:279-87
   PubMedGoogle Scholar
• Seidel MF, Wise BL, Lane NE. Nerve growth factor: an update on the science and therapy. Osteoarthritis Cartilage 2013;21:1223-8
   PubMed Web of Science ®Google Scholar
• McKelvey L, Shorten GD, O’Keeffe GW. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem 2013;124:276-89
   PubMed Web of Science ®Google Scholar
• Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 2008;22:349-59
   PubMed Web of Science ®Google Scholar
• Sanga P, Katz N, Polverejan E, et al. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain 2013;154:1910-19
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M. Targeting Nerve Growth Factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar